NCT02408263

Brief Summary

Pain has been defined as a subjective experience. Various pain assessment tools, (such as NRS) have been developed and validated to objectively monitor and treat pain. There are certain patient populations, in whom, the current pain assessment tools cannot be used effectively due to communication problems such as cognitively impaired patients. In the US, the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) has made it mandatory to monitor and treat pain. In the absence of reliable pain assessment tools that would objectively measure pain, there is also risk of under treatment and overtreatment of pain that may lead to negative outcomes. Therefore, a monitor that is able to predict pain levels objectively, will help to achieve above goals. The investigators are using Skin Conductance Algesimeter (SCA) to measure pain by analyzing changes in skin conductance.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Nov 2010

Shorter than P25 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2010

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2011

Completed
3.6 years until next milestone

First Submitted

Initial submission to the registry

February 17, 2015

Completed
2 months until next milestone

First Posted

Study publicly available on registry

April 3, 2015

Completed
2.7 years until next milestone

Results Posted

Study results publicly available

December 18, 2017

Completed
Last Updated

August 28, 2019

Status Verified

August 1, 2019

Enrollment Period

8 months

First QC Date

February 17, 2015

Results QC Date

March 27, 2017

Last Update Submit

August 13, 2019

Conditions

Outcome Measures

Primary Outcomes (2)

  • Numeric Pain Rating Scale

    Numeric Pain Rating Scale, 0 (no pain) to 10 (worst pain)

    Baseline, Postoperative day 1, Postoperative Day 2

  • Skin Conductance Response

    A skin conductance response is defined as a minimum followed by a maximum in conductance values micro Siemens (mS).

    Baseline, Postoperative day 1, Postoperative day 2

Secondary Outcomes (1)

  • Nausea

    Baseline, Postoperative day 1, Postoperative day 2

Study Arms (1)

Total Hip Replacement (THR) and Total Knee Replacement (TKR)

25 patients receiving a THR and 25 patients receiving aTKR. The investigators are using Skin Conductance Algesimeter (SCA) to measure pain by analyzing changes in skin conductance.

Procedure: Total Hip Replacement (THR) and Total Knee Replacement (TKR)

Interventions

Total Hip Replacement is a surgical procedure where the cartilage and bone of the hip joint is replaced with artificial materials. Total Knee Replacement involves replacement of all three compartments of the knee the medial, the lateral and patellofemoral compartment.

Total Hip Replacement (THR) and Total Knee Replacement (TKR)

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients undergoing surgery for unilateral Total Hip Replacement and Total Knee Replacement.

You may qualify if:

  • Patients undergoing unilateral THR and TKR who are between the ages of 18 and 85 regardless of the anesthesia and postoperative analgesia type.
  • Patients participating in other studies may participate in this study as well
  • Patients with Motor Activity Assessment Scale (MAAS) Score of 3 and 4

You may not qualify if:

  • Age \<18, \>85
  • History of chronic pain as defined by use of long acting opioid medication \> 6 months duration.
  • MAAS Score of \<3 and \>4.
  • Anticholinergic agent use
  • Patients with the following conditions:
  • Autonomic neuropathy
  • Pacemaker/AICD
  • Burn patients or patients with severe dermatologic conditions (as defined by skin conditions causing further pain to patients that actively has to be treated)
  • Allergy to adhesive tape
  • Communication barriers
  • Bilateral Procedures
  • Patient with diagnosis of
  • Dysautonomia
  • Sympathetic dysfunction such as: Raynaud disease, Buerger disease
  • Disorders of sweating such as: Acquired idiopathic generalized anhidrosis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (3)

  • Devlin JW, Boleski G, Mlynarek M, Nerenz DR, Peterson E, Jankowski M, Horst HM, Zarowitz BJ. Motor Activity Assessment Scale: a valid and reliable sedation scale for use with mechanically ventilated patients in an adult surgical intensive care unit. Crit Care Med. 1999 Jul;27(7):1271-5. doi: 10.1097/00003246-199907000-00008.

    PMID: 10446819BACKGROUND
  • Kunimoto M, Kirno K, Elam M, Wallin BG. Neuroeffector characteristics of sweat glands in the human hand activated by regular neural stimuli. J Physiol. 1991 Oct;442:391-411. doi: 10.1113/jphysiol.1991.sp018799.

    PMID: 1798033BACKGROUND
  • Storm H, Shafiei M, Myre K, Raeder J. Palmar skin conductance compared to a developed stress score and to noxious and awakening stimuli on patients in anaesthesia. Acta Anaesthesiol Scand. 2005 Jul;49(6):798-803. doi: 10.1111/j.1399-6576.2005.00665.x.

    PMID: 15954962BACKGROUND

MeSH Terms

Conditions

Pain, Postoperative

Interventions

Arthroplasty, Replacement, HipThreonineArthroplasty, Replacement, Knee

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

Arthroplasty, ReplacementArthroplastyOrthopedic ProceduresSurgical Procedures, OperativePlastic Surgery ProceduresProsthesis ImplantationAmino Acids, EssentialAmino AcidsAmino Acids, Peptides, and ProteinsAmino Acids, Neutral

Results Point of Contact

Title
Dr. Gungor
Organization
HSS

Study Officials

  • Semih Gungor, MD

    Hospital for Special Surgery, New York

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 17, 2015

First Posted

April 3, 2015

Study Start

November 1, 2010

Primary Completion

July 1, 2011

Study Completion

July 1, 2011

Last Updated

August 28, 2019

Results First Posted

December 18, 2017

Record last verified: 2019-08